Envoy Medical (NASDAQ: COCHW) appoints Charles McKhann as independent director
Rhea-AI Filing Summary
Envoy Medical, Inc. announced that its Board of Directors appointed Charles S. McKhann as a Class I director, with his initial term running until the company’s 2027 annual meeting of stockholders. In connection with his appointment, the Board size increased from six to seven members.
Mr. McKhann also joined the Board’s Compensation Committee and was granted stock options to purchase 100,000 shares of Class A Common Stock at an exercise price of $0.72 per share, vesting in 36 equal monthly installments. The Board determined that he qualifies as an independent director under Nasdaq and SEC standards.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after appointment: 7 directors
Stock options granted: 100,000 shares
Option exercise price: $0.72 per share
+3 more
6 metrics
Board size after appointment
7 directors
Board increased from six to seven members upon McKhann’s appointment
Stock options granted
100,000 shares
Options to purchase Class A Common Stock awarded to McKhann at appointment
Option exercise price
$0.72 per share
Exercise price for McKhann’s 100,000 stock options
Vesting schedule
36 monthly installments
McKhann’s stock options vest in 36 equal monthly installments
Warrant exercise price
$11.50 per share
Exchange-listed redeemable warrants exercisable for Class A Common Stock
Par value per share
$0.0001 per share
Par value of Envoy Medical Class A Common Stock
Key Terms
Class I director, Compensation Committee, independent director, Redeemable Warrants, +1 more
5 terms
Class I director financial
"the Board appointed Charles S. McKhann to serve as a Class I director"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Compensation Committee financial
"he was also appointed to the Board’s Compensation Committee"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
independent director financial
"The Board has determined that Mr. McKhann is an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Redeemable Warrants financial
"Redeemable Warrants, each whole Warrant exercisable for one share"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
indemnification agreement financial
"McKhann also entered into the Company’s standard indemnification agreement for officers directors"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Envoy Medical (COCHW) announce in this Form 8-K?
Envoy Medical announced the appointment of Charles S. McKhann as a Class I director and member of its Compensation Committee, expanding the Board from six to seven members. The filing also discloses his equity compensation through stock options and confirms his independent director status.
Who is Charles S. McKhann, newly appointed to Envoy Medical (COCHW)?
Charles S. McKhann is an experienced medical device executive and director, with prior leadership roles at Silk Road Medical and Apollo Endosurgery and board roles at Exagen and Distalmotion. He holds a B.A. and an M.B.A. from Stanford University, bringing significant commercial and leadership experience.
What stock option award did Envoy Medical (COCHW) grant to Charles S. McKhann?
Envoy Medical granted Charles S. McKhann options to purchase 100,000 shares of its Class A Common Stock at an exercise price of $0.72 per share. These stock options vest in 36 equal monthly installments starting from his appointment date to the Board of Directors.
Is Charles S. McKhann considered an independent director at Envoy Medical (COCHW)?
Yes. Envoy Medical’s Board determined that Charles S. McKhann qualifies as an independent director under Nasdaq Capital Market listing requirements and Securities and Exchange Commission standards, including enhanced independence criteria that apply specifically to members of the company’s Compensation Committee.
How did Envoy Medical’s (COCHW) Board structure change with this appointment?
With Charles S. McKhann’s appointment, Envoy Medical’s Board of Directors increased in size from six to seven members. He will serve as a Class I director with an initial term expiring at the company’s 2027 annual meeting of stockholders, adding governance depth.